MONTRÉAL, Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections, announced today the closing of a $4.1 million Series A financing. The round was led by Lumira Capital Investment Management via its Merck …